Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation?

European Journal of Cancer

Volumn 45, Issue 4, 2009, Pages 527-535

  Lonning P E ^a  

^a UNIVERSITY OF BERGEN   (Norway)

Author keywords

Aromatase; Breast cancer; Endocrine therapy; Inhibition; Resistance

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANDROGEN; AROMATASE INHIBITOR; EXEMESTANE; FADROZOLE; FORMESTANE; GROWTH FACTOR; LETROZOLE; PYRIDOGLUTETHIMIDE; TAMOXIFEN;

ADVANCED CANCER; AROMATIZATION; ARTICLE; BIOLOGICAL TRAIT; BREAST CANCER; CROSS RESISTANCE; DNA POLYMORPHISM; DRUG STRUCTURE; ENZYME INHIBITION; ESTROGEN BLOOD LEVEL; GENE EXPRESSION; HUMAN; PRIORITY JOURNAL;

ANDROGENS; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS;

EID: 60349130840     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.10.019     Document Type: Article

References (89)

1. Jones A.L., Powles T.J., Law M., et al. Adjuvant aminoglutethimide for postmenopausal patients with primary breast cancer: Analysis at 8 years. J Clin Oncol 10 10 (1992) 1547-1552
2. Boccardo F., Rubagotti A., Amoroso D., et al. Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: Results of an Italian cooperative study. J Clin Oncol 19 22 (2001) 4209-4215
3. Boccardo F., Rubagotti A., Puntoni M., et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer Preliminary results of the Italian Tamoxifen Anastrozole trial. J Clin Oncol 23 22 (2005) 5138-5147
4. Forbes J.F., Cuzick J., Buzdar A., Howell A., Tobias J.S., and Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9 1 (2008) 45-53
5. Thurlimann B., Keshaviah A., Coates A.S., et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353 26 (2005) 2747-2757
6. Jakesz R., Jonat W., Gnant M., et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366 9484 (2005) 455-462
7. Jakesz R., Greil R., Gnant M., et al. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: Results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Institute 99 24 (2007) 1845-1853
8. Coombes R.C., Kilburn L.S., Snowdon C.F., et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369 9561 (2007) 559-570
9. Goss P.E., Ingle J.N., Martino S., et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349 19 (2003) 1793-1802
10. Mamounas E.P., Jeong J.H., Wickerham D.L., et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial. J Clin Oncol 26 12 (2008) 1965-1971
11. Mouridsen H., Gershanovich M., Sun Y., et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19 (2001) 2596-2606
12. Kaufmann M., Bajetta E., Dirix L.Y., et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. J Clin Oncol 18 (2000) 1399-1411
13. Dombernowsky P., Smith I., Falkson G., et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16 2 (1998) 453-461
14. Gershanovich M., Chaudri H.A., Campos D., et al. Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 25 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Ann Oncol 9 6 (1998) 639-645
15. Lønning P.E. Aromatase inhibitors and inactivators for breast cancer therapy. Drugs Aging 19 4 (2002) 277-298
16. Murray R., and Pitt P. Aromatase inhibition with 4-OHandrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer. Breast Cancer Res Treat 35 (1995) 249-253
17. Carlini P., Frassoldati A., De Marco S., et al. Formestane, a steroidal aromatase inhibitor after failure of non-steroidal aromatase inhibitors (anastrozole and letrozole): Is a clinical benefit still achievable?. Ann Oncol 12 11 (2001) 1539-1543
18. Carlini P., Ferretti G., Di Cosimo S., et al. Is there a benefit by the sequence anastrozole-formestane for postmenopausal metastatic breast cancer women?. J Steroid Biochem Mol Biol 86 1 (2003) 107-109
19. Thürlimann B., Paridaens R., Serin D., et al. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Eur J Cancer 33 11 (1997) 1767-1773
20. Iaffaioli R., Formato R., Tortoriello A., et al. Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer. Brit J Cancer 92 9 (2005) 1621-1625
21. Lønning P.E., Bajetta E., Murray R., et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: A phase II trial. J Clin Oncol 18 11 (2000) 2234-2244
22. Bertelli G., Garrone O., Merlano M., et al. Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer. Oncology 69 6 (2005) 471-477
23. Mayordomo J., Llombart A., Martin M., et al. Randomized multicenter crossover phase II trial to compare exemestane (E) vs. anastrozole (A) in postmenopausal patients (pt) with advanced breast cancer (ABC) and positive hormone receptors (HR). Final efficacy analysis of GEICAM 2001-03 study. J Clin Oncol 24 18 (2006) 37S
24. Steele N., Zekri J., Coleman R., et al. Exemestane in metastatic breast cancer: effective therapy after third-generation non-steroidal aromatase inhibitor failure. Breast 15 3 (2006) 430-436
25. Chin Y.S., Beresford M.J., Ravichandran D., and Makris A. Exemestane after non-steroidal aromatase inhibitors for post-menopausal women with advanced breast cancer. Breast 16 4 (2007) 436-439
26. Carlini P., Michelotti A., Ferretti G., et al. Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients. Cancer Invest 25 2 (2007) 102-105
27. Gennatas C., Michalaki V., Carvounis E., et al. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on letrozole or anastrozole. A phase II trial conducted by the Hellenic Group of Oncology (HELGO). Tumori 92 1 (2006) 13-17
28. HarperWynne C., and Coombes R.C. Anastrozole shows evidence of activity in postmenopausal patients who have responded or stabilised on formestane therapy. Eur J Cancer 35 5 (1999) 744-746
29. Geisler J., Johannessen D.C., Anker G., and Lønning P.E. Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated cancer patients: Clinical and endocrine effects. Eur J Cancer 32A (1996) 789-792
30. Chia S., Gradishar W., Mauriac L., et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: Results from EFECT. J Clin Oncol 26 10 (2008) 1664-1670
31. Ellis M.J., Coop A., Singh B., et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 19 18 (2001) 3808-3816
32. Dowsett M., Cuzick J., Wale C., Howell T., Houghton J., and Baum M. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol 23 30 (2005) 7512-7517
33. McGuire W.L., Horwitz K.B., Pearson O.H., and Segaloff A. Current status of estrogen and progesterone receptors in breast cancer. Cancer 39 6 (1977) 2934-2947
34. Dowsett M., Allred C., Knox J., et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial. J Clin Oncol 26 7 (2008) 1059-1065
35. Rasmussen B.B., Regan M.M., Lykkesfeldt A.E., et al. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol 9 1 (2008) 23-28
36. Geisler J., and Lonning P.E. Endocrine effects of aromatase inhibitors and inactivators in vivo: Review of data and method limitations. J Steroid Biochem Mol Biol 95 1-5 (2005) 75-81
37. Dixon J.M., Renshaw L., Young O., et al. Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer. J Clin Oncol 26 10 (2008) 1671-1676
38. Dowsett M., Goss P.E., Powles T.J., et al. Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: Optimization of therapeutic dose and route. Cancer Res 47 (1987) 1957-1961
39. Lønning P.E., and Ekse D. A sensitive assay for measurement of plasma estrone sulphate in patients on treatment with aromatase inhibitors. J Steroid Biochem Mol Biol 55 3/4 (1995) 409-412
40. Geisler J., Ekse D., Helle H., Duong N., and Lønning P. An optimised, highly sensitive radioimmunoassay for the simultaneous measurement of estrone, estradiol and estrone sulfate in the ultra-low range in human plasma samples. J Steroid Biochem Mol Biol 109 (2008) 90-95
41. Santen R.J., Santner S., Davis B., Veldhuis J., Samojlik E., and Ruby E. Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. J Clin Endocrinol Metab 47 (1978) 1257-1265
42. Lønning P.E., Skulstad P., Sunde A., and Thorsen T. Separation of urinary metabolites of radiolabelled estrogens in man by HPLC. J Steroid Biochem 32 (1989) 91-97
43. Jacobs S., Lønning P.E., Haynes B., Griggs L., and Dowsett M. Measurement of aromatisation by a urine technique suitable for the evaluation of aromatase inhibitors in vivo. J Enzyme Inhibition 4 (1991) 315-325
44. Lønning P.E., Jacobs S., Jones A., Haynes B., Powles T., and Dowsett M. The influence of CGS 16949A on peripheral aromatisation in breast cancer patients. Brit J Cancer 63 (1991) 789-793
45. Jones A.L., MacNeill F., Jacobs S., Lønning P.E., Dowsett M., and Powles T.J. The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients. Eur J Cancer 28A (1992) 1712-1716
46. MacNeill F.A., Jones A.L., Jacobs S., Lønning P.E., Powles T.J., and Dowsett M. The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer. Brit J Cancer 66 (1992) 692-697
47. MacNeill F.A., Jacobs S., Dowsett M., Lønning P.E., and Powles T.J. The effects of oral 4-hydroxyandrostenedione on peripheral aromatisation in post-menopausal breast cancer patients. Cancer Chemother Pharmacol 36 (1995) 249-254
48. MacNeill F.A., Jacobs S., Lønning P.E., Powles T.J., and Dowsett M. Combined treatment with 4-hydroxyandrostenedione and aminoglutethimide: Effects on aromatase inhibition and oestrogen suppression. Brit J Cancer 69 (1994) 1171-1175
49. ®), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Brit J Cancer 74 (1996) 1286-1291
50. Geisler J., King N., Anker G., et al. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 4 (1998) 2089-2093
51. Geisler J., Haynes B., Anker G., Dowsett M., and Lønning P.E. Influence of letrozole (Femara) and anastrozole (Arimidex) on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over-designed study. J Clin Oncol 20 (2002) 751-757
52. Geisler J., Dowsett M., and Lønning P.E. Letrozole is more effective than anastrozole in suppressing total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients. Am J Oncol Rev 1 2 (2002) 99-102
53. vanLandeghem A.A.J., Poortman J., Nabuurs M., and Thijssen J.H.H. Endogenous concentration and subcellular distribution of estrogens in normal and malignant breast tissue. Cancer Res 45 (1985) 2900-2904
54. Sasano H., Anderson T.J., Silverberg S.G., et al. The validation of new aromatase monoclonal antibodies for immunohistochemistry - A correlation with biochemical activities in 46 cases of breast cancer. J Steroid Biochem Mol Biol 95 1-5 (2005) 35-39
55. Miller W.R., and O'Neill J. The importance of local synthesis of estrogen within the breast. Steroids 50 4-6 (1987) 537-548
56. Masamura S., Santner S.J., Gimotty P., George J., and Santen R.J. Mechanism for maintenance of high breast tumor estradiol concentrations in the absence of ovarian function: Role of very high affinity tissue uptake. Breast Cancer Res Treat 42 3 (1997) 215-226
57. Geisler J., Detre S., Berntsen H., Ottestad L., Lindtjørn B., Dowsett M., et al. Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer. Clin Cancer Res 7 (2001) 1230-1236
58. Geisler J., Helle H., Ekse D., et al. Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels. Clin Cancer Res 14 (2008) 6330-6335
59. Lønning P.E. Stepwise estrogen suppression manipulating the estrostat. J Steroid Biochem Mol Biol 79 1-5 (2001) 127-132
60. Lønning P.E., Dowsett M., and Powles T.J. Postmenopausal estrogen synthesis and metabolism: Alterations caused by aromatase inhibitors used for the treatment of breast cancer. J Steroid Biochem 35 (1990) 355-366
61. Bulun S.E., Sebastian S., Takayama K., Suzuki T., Sasano H., and Shozu M. The human CYP19 (aromatase P450) gene: update on physiologic roles and genomic organization of promoters. J Steroid Biochem Mol Biol 86 3-5 (2003) 219-224
62. Chen S., Ye J.J., Kijima I., Kinoshita Y., and Zhou D.J. Positive and negative transcriptional regulation of aromatase expression in human breast cancer tissue. J Steroid Biochem Mol Biol 95 1-5 (2005) 17-23
63. Ma C.X., Adjei A.A., Salavaggione O.E., et al. Human aromatase: Gene resequencing and functional genomics. Cancer Res 65 23 (2005) 11071-11082
64. Colomer R., Monzo M., Tusquets I., et al. A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma. Clin Cancer Res 14 3 (2008) 811-816
65. Miller W.R. Aromatase inhibitors in the treatment of advanced breast cancer. Cancer Treat Rev 16 (1989) 83-93
66. Brodie A.M.H., Garrett W.M., Hendrickson J.R., Tsai-Morris C.-.H., Marcotte P.A., and Robinson C.H. Inactivation of aromatase in vitro by 4-hydroxy-4-androstene-3, 17-dione and 4-acetoxy-4-androstene-3, 17-dione and sustained effects in vivo. Steroids 38 (1981) 693-702
67. Covey D.F., and Hood W.F. Enzyme-generated intermediates derived from 4-androstene-3, 6, 17-trione and 1, 4, 6-androstatriene-3, 17-dione cause a time-dependent decrease in human placental aromatase-activity. Endocrinology 108 4 (1981) 1597-1599
68. Di Salle E., Ornati G., Giudici D., Lassus M., Evans T.R.J., and Coombes R.C. Exemestane (FCE 24304), a new steroidal aromatase inhibitor. J Steroid Biochem Mol Biol 43 (1992) 137-143
69. Miller W.R., and Dixon J.M. Local endocrine effects of aromatase inhibitors within the breast. J Steroid Biochem Mol Biol 79 1-5 (2001) 93-102
70. Miller W.R., and Dixon J.M. Antiaromatase agents: preclinical data and neoadjuvant therapy. Clin Breast Cancer 1 Suppl. 1 (2000) s9-s14
71. Hong Y., Cho M., Yuan Y.C., and Chen S. Molecular basis for the interaction of four different classes of substrates and inhibitors with human aromatase. Biochem Pharmacol 75 5 (2008) 1161-1169
72. Hong Y.Y., Yu B., Sherman M., Yuan Y.C., Zhou D.J., and Chen S.A. Molecular basis for the aromatization reaction and exemestane-mediated irreversible inhibition of human aromatase. Mol Endocrinol 21 2 (2007) 401-414
73. Wang X., and Chen S.U. Aromatase destabilizer: Novel action of exemestane, a food and drug administration-approved aromatase inhibitor. Cancer Res 66 21 (2006) 10281-10286
74. Dowsett M., Cunningham D.C., Stein R.C., et al. Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients. Cancer Res 49 (1989) 1306-1312
75. Johannessen D.C., Engan T., Ed Salle., et al. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: A phase I study. Clin Cancer Res 3 (1997) 1101-1108
76. Ariazi E.A., Leitao A., Oprea T.I., et al. Exemestane's 17-hydroxylated metabolite exerts biological effects as an androgen. Mol Cancer Ther 6 11 (2007) 2817-2827
77. Dowsett M., Mehta A., King N., et al. An endocrine and pharmacokinetic study of four oral doses of formestane in postmenopausal breast cancer patients. Eur J Cancer 28 (1992) 415-420
78. Lea O.A., Kvinnsland S., and Thorsen T. Improved measurement of androgen receptors in human breast cancer. Cancer Res 49 (1989) 7162-7167
79. Ando S., De Amicis F., Rago V., et al. Breast cancer: from estrogen to androgen receptor. Mol Cell Endocrinol 193 1-2 (2002) 121-128
80. Nevinny H.B., Haines C.R., Dederick M.M., and Hall T.C. Comparative study of 6-dehydro-17alpha-methyltestosterone + testosterone propionate in human breast cancer. Cancer 17 1 (1964) 95
81. Macedo L.F., Guo Z.Y., Tilghman S.L., Sabnis G.J., Qiu Y., and Brodie A. Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole. Cancer Res 66 15 (2006) 7775-7782
82. Suzuki T., Miki Y., Moriya T., et al. 5 Alpha-reductase type 1 and aromatase in breast carcinoma as regulators of in situ androgen production. Int J Cancer 120 2 (2007) 285-291
83. Zhu L., Chow L.W., Loo W.T., Guan X.Y., and Toi M. Her2/neu expression predicts the response to antiaromatase neoadjuvant therapy in primary breast cancer: subgroup analysis from celecoxib antiaromatase neoadjuvant trial. Clin Cancer Res 10 14 (2004) 4639-4644
84. Wang X., Masri S., Phung S., and Chen S.U. The role of amphiregulin in exemestane-resistant breast cancer cells: Evidence of an autocrine loop. Cancer Res 68 7 (2008) 2259-2265
85. Masri S., Phung S., Wang X., Wu X.W., Yuan Y.C., Wagman L., et al. Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor. Cancer Res 68 12 (2008) 4910-4918
86. Lundgren S., Gundersen S., Klepp R., Lønning P.E., Lund E., and Kvinnsland S. Megestrol acetate versus aminoglutethimide for metastatic breast cancer. Breast Cancer Res Treat 14 (1989) 201-206
87. Lundgren S. Progestins in breast cancer treatment. Acta Oncol 31 (1992) 709-722
88. Jones S., Vogel C., Arkhipov A., et al. Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. J Clin Oncol 17 11 (1999) 3418-3425
89. Lundgren S., Helle S.I., and Lønning P.E. Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients. Clin Cancer Res 2 (1996) 1515-1521